OCRA Early Career Investigator Grant Program

Deadline: 25-Mar-2026

The Ovarian Cancer Research Alliance (OCRA) is accepting Letters of Intent (LOIs) for its 2027 Early Career Investigator Grant. The program provides up to USD 450,000 over three years to junior faculty conducting innovative research in ovarian and related gynecologic cancers. Eligible applicants must be within seven years of their first academic appointment and commit 50–75% effort to cancer research.

OCRA 2027 Early Career Investigator Grant

The Ovarian Cancer Research Alliance (OCRA) Early Career Investigator Grant supports junior faculty pursuing independent research careers in ovarian cancer and related gynecologic cancers.

The grant funds creative, original, and high-impact research projects while strengthening the academic development of emerging investigators in this specialized oncology field.

About the Ovarian Cancer Research Alliance (OCRA)

The Ovarian Cancer Research Alliance (OCRA) is a nonprofit organization dedicated to advancing ovarian cancer research, improving early detection and treatment, and supporting patients.

Through targeted grant programs, OCRA invests in high-potential researchers and accelerates progress in gynecologic cancer science.

Purpose of the Early Career Investigator Grant

The 2027 grant cycle aims to:

• Advance research in ovarian and related gynecologic cancers

• Support early detection, prevention, treatment, and translational research

• Foster independent research careers among junior faculty

• Enable substantial protected time for meaningful research engagement

This award is designed to help promising investigators transition toward full research independence.

Research Focus Areas

Projects must focus on ovarian cancer or closely related gynecologic cancers and may include:

1. Early Detection

• Biomarker discovery

• Screening technologies

• Risk stratification tools

2. Prevention

• Genetic and molecular risk analysis

• Preventive interventions

• Population-level risk reduction strategies

3. Treatment Innovation

• Novel therapeutics

• Drug resistance mechanisms

• Precision oncology approaches

4. Translational Research

• Bench-to-bedside research

• Clinical application of laboratory findings

• Integration of clinical and molecular data

Projects must demonstrate originality, feasibility, and high potential impact.

Funding Details

• Up to USD 150,000 per year

• Duration: 3 years

• Total maximum funding: USD 450,000

• Funds are awarded to the Principal Investigator’s institution

• Anticipated project start date: February 1, 2027

Recipients must submit activation documents and annual narrative and financial reports.

All publications and presentations must acknowledge OCRA funding support.

Who Is Eligible?

Principal Investigator Requirements

Applicants must:

• Hold an MD, DO, and/or PhD degree

• Be within 7 years of their initial academic appointment after fellowship or postdoctoral training

• Hold the rank of Assistant Professor or equivalent

• Or begin such a position by July 2026

Institutional Requirements

Applicants must be affiliated with:

• Accredited schools of medicine

• Schools of public health

• Recognized nonprofit scientific research institutions

Institutions must conduct the research directly.

For-profit organizations are not eligible.

Effort Commitment Requirements

• Investigators with clinical responsibilities must dedicate at least 50% of professional time to ovarian or related gynecologic cancer research.

• Investigators without clinical responsibilities must dedicate at least 75% effort to such research.

Ineligible Applicants

The following are not eligible:

• Individuals who currently hold or previously held substantial early-career development grants

• Recipients of independent research grants such as NIH R01 awards

• Applicants serving as Principal Investigator on more than one LOI in the same OCRA cycle

• Individuals holding more than one active OCRA grant

• Prior recipients of this specific Early Career Investigator Grant

Key Definitions for Clarity

Early Career Investigator
A junior faculty member progressing toward research independence within seven years of their first academic appointment.

Translational Research
Research that applies laboratory discoveries to clinical settings to improve patient outcomes.

Substantial Early-Career Funding
Multi-year career development awards or independent grants that already provide long-term research independence support.

Protected Research Time
Designated professional time allocated specifically for research activities rather than clinical or administrative duties.

Why This Grant Matters

Ovarian cancer remains one of the most lethal gynecologic cancers due to late detection and limited early screening tools.

This grant:

• Builds the pipeline of independent ovarian cancer researchers

• Provides meaningful protected time for focused research

• Accelerates innovation in early detection and therapy

• Strengthens institutional research capacity

By supporting early-career investigators, OCRA ensures long-term progress in ovarian cancer science.

How to Apply

Step 1: Confirm Eligibility

Review academic appointment date, degree status, institutional affiliation, and funding history.

Step 2: Prepare Letter of Intent (LOI)

The LOI should clearly outline:

• Research hypothesis

• Study design

• Innovation and originality

• Expected impact

• Career development plan

• Institutional support

Step 3: Institutional Coordination

Ensure:

• Institutional eligibility

• Commitment to protected research time

• Administrative approval

Step 4: Submit LOI

Submit within the OCRA grant cycle timeline.

Only one LOI per applicant per grant cycle is allowed.

Step 5: Full Application (If Invited)

Selected applicants will be invited to submit a detailed proposal including:

• Budget justification

• Research timeline

• Compliance documentation

• Letters of support

Common Mistakes to Avoid

1. Applying despite holding major independent funding (e.g., NIH R01).

2. Failing to meet protected time requirements.

3. Submitting without institutional verification of eligibility.

4. Providing unclear research objectives or vague methodology.

5. Overlooking publication acknowledgment requirements.

Careful eligibility review is critical before submission.

Frequently Asked Questions (FAQs)

1. How much funding is available?

Up to USD 450,000 total, distributed as USD 150,000 annually for three years.

2. Who can apply?

Junior faculty within seven years of their first academic appointment at the Assistant Professor level or equivalent.

3. Are clinicians eligible?

Yes, provided they dedicate at least 50% of their professional time to ovarian or related gynecologic cancer research.

4. Can someone with an NIH R01 apply?

No. Investigators who currently hold or previously held independent research grants such as NIH R01 awards are not eligible.

5. Can for-profit institutions apply?

No. Only accredited academic and nonprofit research institutions that conduct the research directly are eligible.

6. Can I submit multiple Letters of Intent?

No. Only one LOI per Principal Investigator per grant cycle across all OCRA opportunities is permitted.

7. Is this award renewable?

No. The Early Career Investigator Grant may be awarded to an individual only once.

Conclusion

The OCRA 2027 Early Career Investigator Grant is a major funding opportunity for junior faculty dedicated to advancing ovarian and related gynecologic cancer research.

With up to USD 450,000 in support and a strong focus on research independence, this program strengthens the next generation of oncology investigators.

Eligible researchers committed to high-impact, innovative cancer research should prepare a competitive Letter of Intent and ensure full compliance with eligibility requirements before applying.

For more information, visit OCRA.